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Abstract 
Immune cells have been implicated in influencing stroke outcomes depending on their temporal dynamics, 
number, and spatial distribution after ischemia. Depending on their activation status, immune cells can 
have detrimental and beneficial properties on tissue outcome after stroke, highlighting the need to 
modulate inflammation towards beneficial and restorative immune responses. Novel dietary therapies 
may promote modulation of pro- and anti-inflammatory immune cell functions. 
Among the dietary interventions inspired by the Mediterranean diet, hydroxytyrosol (HT), the main 
phenolic component of the extra virgin olive oil (EVOO), has been suggested to have antioxidant and 
anti-inflammatory properties in vitro. However, immunomodulatory effects of HT have not yet been 
studied in vivo after stroke. 
The aim of this project is therefore to monitor the therapeutic effect of a HT-enriched diet in an 
experimental stroke model using non-invasive in vivo multimodal imaging, behavioural phenotyping and 
cross-correlation with ex vivo parameters. 
Methods: A total of N = 22 male C57BL/6 mice were fed with either a standard chow (n = 11) or a HT 
enriched diet (n = 11) for 35 days, following a 30 min transient middle cerebral artery occlusion (tMCAo). 
T2-weighted (lesion) and perfusion (cerebral blood flow)-/diffusion (cellular density)-weighted MR images 
were acquired at days 1, 3, 7, 14, 21 and 30 post ischemia. [18F]DPA-714 (TSPO, neuroinflammation 
marker) PET-CT scans were acquired at days 7, 14, 21 and 30 post ischemia. Infarct volume (mm3), 
cerebral blood flow (mL/100g/min), apparent diffusion coefficient (10-4·mm2/s) and percentage of injected 
tracer dose (%ID/mL) were assessed. 
Behavioural tests (grip test, rotarod, open field, pole test) were performed prior and after ischemia to 









Ex vivo analyses (IHC, IF, WB) were performed to quantify TSPO expression, immune cells including 
microglia/macrophages (Iba-1, F4/80), astrocytes (GFAP) and peripheral markers in serum such as 
thiobarbituric acid reactive substances (TBARS) and nitric oxide (NO) 35 days post ischemia. 
Additionally, gene expression of pro- and anti-inflammatory markers were assessed by rt-qPCR, including 
tspo, cd163, arg1, tnf and Il-1β. 
Results: No treatment effect was observed on temporal [18F]DPA-714 uptake within the ischemic and 
contralateral region (two-way RM ANOVA, p = 0.71). Quantification of the percentage of TSPO+ area by 
immunoreactivity indicated a slight 2-fold increase in TSPO expression within the infarct region in HT-fed 
mice at day 35 post ischemia (p = 0.011) correlating with a 2-3 fold increase in Iba-1+ cell population 
expressing CD163 as anti-inflammatory marker (R2 = 0.80). Most of the GFAP+ cells were TSPO-. Only 
few F4/80+ cells were observed at day 35 post ischemia in both groups. 
No significant treatment effect was observed on global ADC and CBF within the infarct and the 
contralateral region over time. Behavioural tests indicated improved strength of the forepaws at day 14 
post ischemia (p = 0.031). 
Conclusion: An HT-enriched diet significantly increased the number of Iba-1+ microglia/macrophages in 
the post-ischemic area, inducing higher expression of anti-inflammatory markers while no clear-cut effect 
was observed. Also, HT did not affect recovery of the cerebrovascular parameters, including ADC and 
CBF. 
Altogether, our data indicated that a prolonged dietary intervention with HT, as a single component of 
the Mediterranean diet, induces molecular changes that may improve stroke outcomes. Therefore, we 
support the use of the Mediterranean diet as a multicomponent therapy approach after stroke. 
Key words: Hydroxytyrosol; transient middle artery occlusion; neuroinflammation; [18]DPA-714; multimodal 
imaging; TSPO 
Introduction 
Decreased cerebral blood flow (CBF) due to the 
occlusion of the blood vessels leads to ischemic stroke. 
Subsequently, activation of pathological mechanisms 
such as oxidative stress, excitotoxicity, inflammation, 
and apoptosis, potentiates the ischemic injury. Each of 
those pathological processes have been the central 
focus of research for new stroke therapies. However, 
the treatment options are still limited: acute treatment 
with the recombinant tissue plasminogen activator to 
resolve obstructive blood clots is the only 
FDA-approved drug for acute intervention, apart 
from mechanical thrombectomy [1,2]. However, it has 
a restrictive time window and may induce severe 
complications [3] such as haemorrhagic 
transformation [4]. Furthermore, no other drug is 
available in clinical practice for the rehabilitation of 
patients at later stages of the disease. 
An ischemic event and potential reperfusion of 
the injured tissue causes a misbalance in the 
production of free radicals (reactive oxygen (ROS) 
and nitrogen (RNS) species) in brain parenchyma and 
periphery [5,6]. Efforts have focused on new 
neuroprotective compounds able to block or scavenge 
the excess of free radicals [3,5]. While animal research 
supported the use of antioxidant agents, most of these 
antioxidants fail to be effective in human clinical trials 
because of the short half-life and/or human 
comorbidities [3,5]. 
Oxidative stress contributes to the post-ischemic 
inflammatory response, with the release of 
inflammatory mediators and concomitant blood-brain 
barrier disruption. As a result, an inflammatory 
environment emerges, driven by activated innate and 
peripheral immune cells playing a pivotal role in 
stroke resolution. Although neuroinflammation (NI) 
is key for tissue repair and remodelling, it may also be 
detrimental by increasing tissue injury [7]. The 
balance between pro- and anti-inflammatory stimuli 
drives the functional polarization of many immune 
cells such as microglia/macrophages (Iba-1+, F4/80+, 
CD11b+ cells), astrocytes (GFAP+ cells) and 
neutrophils into beneficial or detrimental phenotypes 
[8,9]. In stroke, microglia/macrophages showed an 
enhanced beneficial anti-inflammatory phenotype 
within the first week, but expressed a more 
detrimental pro-inflammatory genes signature at later 
stages [8,10], peaking around day 14 post ischemia 
[11]. However, the concept of differential waves of 
anti- and pro-inflammatory microglia is still too 
simplistic to illustrate the complex spatiotemporal 
changes of the transcriptomic and proteomic 
microglial profile in response to injury [12,13]. 
Although both processes occur sequentially, the 
anti-inflammatory response might not be sufficient 
very early after stroke to balance the detrimental 
effects of the pro-inflammatory burst. The degree and 
heterogeneity of immune cells in post-ischemic tissues 
make the inflammatory response a potential drug 
target for stroke immunotherapy [8,14]. Therapeutic 
strategies include enhancing an anti-inflammatory 





environment, inhibition of pro-inflammatory stimuli 
and a phenotypical switch toward an 
anti-inflammatory phenotype. Despite significant 
advances towards better therapies, no 
immunomodulatory drugs are available yet [7,10,14]. 
The future success of immunomodulatory therapies 
rely on the elucidation of the immune interactions and 
promote tissue repair [15]. 
Hydroxytyrosol (3,4-dihydroxyphenyl-ethanol, 
HT) [16] is recognized as a potent antioxidant, anti- 
inflammatory, and neuroprotective molecule [17–20]. 
HT is redundantly associated to the Mediterranean 
diet since it is the main phenolic compound of the 
extra virgin olive oil (EVOO) extracts [20–24]. Human 
trials indicated that an EVOO-based Mediterranean 
diet reduced the risk of stroke [25,26], raising interest 
as a complementary beneficial approach. HT exerts a 
wide range of beneficial effects while mechanisms of 
action are still unclear [17]. HT elicits direct 
scavenging effects on ROS/RNS but also activates 
mechanisms that counteract oxidative damage 
[6,17,24], by protecting viable tissue and vascular cells 
[24,27]. Concomitant with its strong antioxidant 
property, HT has been reported to possess high 
anti-inflammatory activity in vitro and in animal 
models of inflammation [17,28,29], by inhibiting the 
production of pro-inflammatory markers [19,29]. In 
vitro evidences showed decreased cyclooxygenase-2 
(COX-2), inducible nitric oxide synthase (iNOS), and 
MMP-9 levels in activated murine macrophages [30], 
and stimulated human monocytes [31], mediated by 
inhibition of the nuclear factor-kB (NF-kB) and 
PKCα/PKCβ1 respectively. However, contradictory 
results in human macrophages were obtained by 
Bigali et al. (2018), showing no effect on iNOS but on 
prostaglandin E2 (PGE2) levels and transcription 
factor Nrf2, overall attenuating inflammation [32]. An 
in vivo study confirmed the reduction of COX-2 and 
tumor necrosis factor alpha (TNF-α) levels in plasma 
in a murine inflammation model [29]. 
Despite its role in preventing ischemic events 
[26,33], the therapeutic effects of HT have been 
scarcely studied in stroke animal models [34]. 
In the present study, we investigated the 
possible therapeutic effects of a HT-enriched diet as 
therapeutic intervention after transient ischemic 
stroke on the neuro-inflammatory response, 
cerebrovascular, and functional parameters in a 
transient middle cerebral artery occlusion (tMCAo) 
mouse model (30 minutes) using in vivo multimodal 
imaging and behavioural tests. To do so, we 
performed a longitudinal positron emission 
tomography (PET)/magnetic resonance (MR) 
imaging study to monitor the underlying mechanisms 
occurring at the different stages of the disease and 
therapy response. We investigated the effects of HT 
on the TSPO-dependent neuroinflammatory reaction, 
the infarct volume and vascular parameters (diffusion 
and perfusion). We also assessed sensorimotor 
functions prior and after surgery and therapy effect 
on motor functions recovery using behavioural tests. 
Blood samples were collected on the last day of the 
experiment to assess peripheral markers including 
nitric oxide (NO) and thiobarbituric acid reactive 
substances (TBARS), as indexes of vascular integrity 
and lipid peroxidation, respectively. Brains were 
collected on the last day of the experiment to 
investigate the cellular source of TSPO expression in 
the chronic phase, including microglia/macrophages 
(Iba-1+, F4/80+), expression of the anti-inflammatory 
marker CD163 and astrocytes (GFAP+). 
We hypothesized that HT may have 
immunomodulatory functions in the post-ischemic 
phase, able to modify the inflammatory landscape. 
Potential therapy effects may be non–invasively 
detected by [18F]DPA-714 as a biomarker for glial 
activation and by T2-weighted MR (lesion), 
diffusion-weighted (cellular density) and 
perfusion-weighted (cerebral blood flow) MR 
imaging. Additionally, beneficial functional outcomes 
may be detected by behavioural tests including open 
field (locomotion), pole test (general motor functions), 




All experiments were conducted in accordance 
with the German Law on the Care and Use of 
Laboratory Animals and approved by the Landesamt 
für Natur, Umwelt und Verbraucherschutz of North 
Rhine-Westphalia and according to the ARRIVE 
guidelines (https://www.nc3rs.org.uk/arrive- 
guidelines) [35]. 
3-4 months old C57BL/6J mice (N = 22, 20-25 g in 
body weight) were housed in a temperature- 
controlled (25 °C) and humidity-controlled (40%) 
facility with a 12:12h light:dark cycle. Food and water 
were available ad libitum. 
After transient MCA occlusion, mice were 
randomly assigned by an external person to either a 
control (n = 11) or a hydroxytyrosol (n = 11) diet. 
Experimenters were blinded during the procedures 
and did not know which animal was assigned to the 
treatment group until the data analysis was 
performed. 
N= 8 mice per group were used for in vivo 
imaging purpose and behavioural assessment. 
Besides, n = 3 mice per group were added for ex vivo 





analysis at day 35 post ischemia. Animals were 
anesthetized, sacrificed by transcardiac perfusion 
after completion of the study, at day 35 post ischemia. 
Brains were removed for further ex vivo analyses. The 
timeline of the experiment design is summarized in 
Figure 1. Additional details on the study design and 
animal number were reported in Supplementary 
Table S1. 
Transient middle cerebral artery occlusion 
(tMCAo) and reperfusion 
A total of N = 22 male C57BL/6J mice, 3-4 
months, old were subjected to a 30 min transient 
middle cerebral artery occlusion (tMCAo) with partial 
reperfusion at day 0 (Figure 1, Figure S1), as 
previously described with minor changes [36,37]. 
Briefly, animals received an i.p. injection of 0.04 mg 
Fentanyl/4 mg Midazolam/1 g bodyweight 
(Fentanyl: RotexMedica, Trittau, Germany; 
Midazolam: Ratiopharm, Ulm, Germany) and were 
anaesthetised with 4% v/v Isoflurane/O2 (Abbott 
Animal Health) and maintained with 2% v/v 
Isoflurane/O2. Body temperature was maintained at 
37 °C with a heating plate system. The regional 
cerebral blood flow (CBF) was monitored by laser 
Doppler flowmetry (Periflux System 5000, Perimed, 
Järfälla, Sweden) during the entire procedure to 
ensure successful occlusion and reperfusion (Figure 
S1). To do so, the laser Doppler probe (PH07-5, 
Perimed, Järfälla, Sweden) was directly fixed on the 
skull above the cortical area perfused by the middle 
cerebral artery (MCA) and the signal was recorded 
with PeriSoft software (Perimed, Järfälla, Sweden). 
Middle cerebral artery occlusion was achieved 
by introducing a silicone-coated 7-0 MCAO 
monofilament (diameter with coating 0.19 ± 0.01 mm) 
(Doccol Corporation, MA, USA) into the distal 
common carotid artery (CCA), following then the 
internal carotid artery upwards to the middle cerebral 
artery. Success occlusion induced the Doppler signal 
to drop by at least 80 % of the baseline signal followed 
by partial reperfusion. The monofilament was fixed 
for 30 minutes before withdrawal. Right after surgery, 
all animals received subcutaneously Buprenorphin 
(0.05-0.1 mg/kg bodyweight) (Indivior, Berkshire, 
UK) for pain relief. Mice were controlled and 
weighted daily during the first week, and then once a 
week until the end of the experiment. Exclusion 
criteria were: (i) absence of lesion on the 
T2w-weighted MR images on day 1 post ischemia, (ii) 
edema volume exceeding the cortical and striatal 
tissues, and (iii) extreme weight loss (> 20% of the 
initial weight). 
Hydroxytyrosol diet 
The hydroxytyrosol diet contained 0.03 gm% 
hydroxytyrosol resulting in an estimated daily HT 
intake of 45 mg/kg body weight daily HT intake 
(Seprox Biotech, Murcia, Spain). Calahorra et al. 
(2019) published individual food intake of the HT diet 
and change in body weight after stroke [34]. Food 
intake decreased within the first week post ischemia 
but increased again afterwards. 
Composition of both control and HT diets 
included 24.0% kcal protein, 15.0% kcal fat and 61.0% 
kcal carbohydrates (Research Diet Services B.V., Wijk 
bij Duurstede, The Netherlands), as previously 
reported [34,38,39]. 
Diets were stored at -20 °C until use. 
Behavioural testing 
Open field, grip test, rotarod, and pole tests were 
performed to evaluate the effects of a HT-enriched 
diet on motor and cognitive dysfunctions after 
ischemia. The four behavioural tests were carried out 
prior to tMCAo and at days 7, 14 and 30 post ischemia 
as indicated in Figure 1. 
 
 
Figure 1. Study design. After a 30 minutes tMCAo, N = 22 mice were randomly divided into a control (green) or HT (red) diet group. MR studies were conducted at days 1, 3, 7, 14, 21 
and 30 post ischemia while [18F]DPA-714 PET scans were acquired at days 7, 14, 21 and 30 post ischemia. Mice were also tested for motor and cognitive impairments using four behavioural 
tests: open field, grip strength test, pole test, and rotarod prior and after a 30 min tMCAo. After the last behavioural test (at day 35), all animals were killed and brains were collected for ex 
vivo analysis. 






The open field test allowed for the assessment of 
behaviour and locomotor activity by recording free 
movements of a mouse. The open field maze consists 
of a squared chamber (40 cm (length) × 40 cm (width) 
× 25 cm (height)) made of non-porous plastic placed 
in a quiet and free of clue environment. The mouse is 
placed in the middle of the maze and can freely move 
for 10 min. Locomotion was automatically recorded 
using EthoVision XT15 (Noldus, Wageningen, The 
Netherlands) video tracking system attached to a pole 
above the field. 
Grip strength test 
The grip strength test allows assessing grip 
strength of a mouse using a grip strength meter 
(Grip-Strength Meter, 47200, Ugo Basile, Italy) to 
determine forelimb and also total limb (fore- and 
hindlimbs combined) muscle strength. 
The grip strength meter is arranged horizontally 
on the table. The mouse is able to grasp the grip 
trapeze with the forepaws or the grid with both fore- 
and hind paws while the experimenter holds the tail. 
The mice are pulled backwards until the grip is 
released. The test is repeated five consecutive times. 
The average of the peak force (in gf) is calculated from 
the last three trials. 
Rotarod 
The rotarod (ITC LifeScience Inc., Woodland 
Hills, CA, USA) test is used to evaluate the motor 
coordination of rodents. In this test, a mouse is placed 
on a rotating rod (3 cm in diameter) suspended 30 cm 
above the protected-rotarod apparatus floor. The 
mouse is placed on the rod and left to acclimatize for 
30 s. Then, the rotarod is turned on to accelerate in 300 
s from 4 to 40 rpm. The trial is complete when the 
mouse falls down. The test is repeated five 
consecutive times. The time spent on the cylinder (in 
seconds) and the covered distance (in centimetres) 
were automatically recorded for each trial. The 
average values are calculated from the last three trials. 
Two-way repeated measures ANOVA indicated no 
treatment, time, or interaction significant effect on run 
distance. Results are reported in Figure S11. 
Pole test 
The pole test is a general test to assess motor 
functions. The mouse is placed head upward just 
below the top of a vertical pole (diameter 2.5 cm; 
height 60 cm) and then allowed to descend into their 
home cage. Each trial is recorded using EthoVision 
XT15 (Noldus, Wageningen, The Netherlands) to 
manually measure the time needed to reach the floor. 
This procedure is repeated five times but only the last 
three trials are used for calculation. 
Two-way repeated measures ANOVA indicated 
no treatment, time or interaction significant effect on 
run distance. Results are reported in Figure S12. 
[18F]DPA-714 PET imaging 
[18F]DPA-714 was prepared as previously 
described [40] with a > 99% radiochemical purity. 
[18F]DPA-714 PET scans were acquired on a 
high-resolution small animal PET scanner (32 module 
quadHIDAC, Oxford Positron Systems Ltd.). 
Once anaesthetized (induction: 5% v/v 
isoflurane/O2), mice were cannulated using a 26G 
catheter (Vasculon Plus, BD, Heidelberg, Germany) 
connected to polyethylene tube filled with NaCl. 
Then, mice were injected 12 ± 3.9 MBq of 
[18F]DPA-714 tracer and kept under anaesthesia (1.5% 
v/v isoflurane/O2) in a warmed environment for 45 
minutes. The PET scan was acquired from 45 to 60 
minutes post injection. 
PET data were reconstructed using one-pass list 
mode expectation maximization algorithm with 
resolution recovery [41,42], allowing reconstruction of 
a large number of coincidence events into a large field 
of view (FOV). Spatial resolution is of 1.07 mm with 
uniform resolution over the entire FOV (280 mm axial 
length, 165 mm diameter). After the PET scan, the 
animal bed was transferred in the computed 
tomography CT scanner (Inveon, Siemens Medical 
Solutions) for anatomic co-registration with the PET 
image. Three molecular sieve spheres (Acros 
Organics, Geel, Belgium) were rinsed in radiotracer 
solution and taped on the extremities of the bed (two 
on the left side and one on the right side). Those 
landmarks are both visible on PET and CT images and 
used for co-registration. 
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) scans 
(Biospec 94/20, Bruker Biospin GmbH, Ettlingen, 
Germany), including T2-weighted (T2w), diffusion 
weighted imaging (DWI) and perfusion weighted 
imaging (PWI), were conducted at days 1, 3, 7, 14, 21 
and 30 after tMCAo. Infarct volume, quantitative 
apparent diffusion coefficient (ADC) and cerebral 
blood flow were calculated. Further experimental 
details can be found in Supplementary Material and 
Methods. 
Image analysis 
The full in vivo imaging dataset was analysed 
using the in-house developed software MEDgical 
dedicated to the analysis of multi-dimensional, 
multi-scale biomedical image data. 
First, all MR images were manually co-registered 
to the corresponding PET-CT scans acquired on the 





same day from the same animal. Then, T2w-MR 
images from day 1 post ischemia were co-registered 
with all the PET-CT scans to visualize spatio-temporal 
distribution of [18F]DPA-714 tracer and quantify the 
regional uptake. 
Besides, co-registered T2w-MR images were 
segmented using a modified atlas-based thresholding 
approach [43] to delineate the infarcted region at days 
1, 3 and 7 post ischemia. Briefly, an atlas-based right 
hemisphere volume of interest (VOI) was segmented 
using a threshold of the mean intensity + 2.5 * 
standard deviation (sd) of the atlas-based 
contralateral striatum. 
The percentage of radiotracer uptake per 
millilitre (%ID/mL) was assessed for all time points 
using the infarct volume defined on the T2w-MR 
image from day 1 and the atlas-based contralateral 
striatum VOI (previously adjusted to the T2w-MR 
images). 
Apparent diffusion coefficient (ADC) maps and 
arterial spin labelling (ASL) maps were co-registered 
with their respective T2w-MR images using our 
in-house developed software. ADC and CBF values 
were assessed within (i) the infarct defined by the 
T2w-MR image from day 1 post ischemia and (ii) its 
mirrored VOI into the contralateral hemisphere. 
Qualitative and quantitative assessments were 
cross-validated using the original data files (2dseq 
files) opened with ImageJ 1.51j software (National 
Institutes of Health, Bethesda, MD, USA). From there, 
infarct-to-contralateral ratios were calculated for both 
ADC and CBF values (Figures shown in 
Supplementary data). 
Tissue processing 
On the last day of the experiment, half of the 
mice were sacrificed by transcardiac perfusion using 
0.1 M phosphate-buffered saline (PBS) followed by 4% 
paraformaldehyde (PFA) in 0.1 M PBS) solution (pH = 
7.4, at 4 °C). The brains were harvested and processed 
for immunohistochemical and immunofluorescent 
staining. 
The other half were only perfused with 0.1 M 
PBS solution. Brains were immediately frozen in 
liquid nitrogen and kept at -80 °C for western blotting. 
Blood samples were collected before sacrifice 
and centrifuged (4 °C). Supernatant and pellet were 
stored at -80 °C until use. 
Plasma analysis 
Serum nitric oxide (NO) concentration was 
determined using an ozone chemiluminescence-based 
assay as previously described [34,44]. Briefly, samples 
were deproteinized (in 0.8 N NaOH and 16% ZnSO4 
buffers) and used for chemiluminescence assay in a 
NO analyser (NOA 280i; Sievers Instruments, 
Boulder, CO, USA). 
Serum thiobarbituric acid reactive substances 
(TBARS) levels were assessed by an adapted method 
previously described [34,45]. 
Analyses indicated no treatment effects on NO 
nor TBARS. Results are reported in Figure S10. 
Immunoreactivity 
5 μm paraffin sections were cut from mouse 
brains fixated in 4% paraformaldehyde and 
subsequently immunohistochemically stained and 
analysed. 
Primary antibodies and dilutions used: anti-PBR 
antibody (anti-PBR, TSPO) (rabbit, 1:250, ab109497, 
Abcam, Cambridge, UK), anti-ionized calcium 
binding adapter molecule 1 (anti-Iba-1) (rabbit, 1:500, 
019-19741, Wako Chemicals USA, Inc. Richmond, VA, 
USA), anti-glial fibrillary acidic protein (anti-GFAP) 
(chicken, 1:500, ab4675, Abcam, Cambridge, UK), 
anti-F4/80 (rat, 1:200, ab6640, Abcam, Cambridge, 
UK) and CD163 (rabbit, 1:50, bs-2527R, Bioss). Tissue 
sections were investigated with a combined 
fluorescent-light microscope (Nikon Eclipse NI-E, 
Nikon, Tokyo, Japan). Details are given in 
Supplementary Material and Methods. 
Western blot 
Western blot was performed to determine 
protein levels in the infarcted and non-infarcted 
hemispheres. Proteins were extracted in a radio- 
immunoprecipitation buffer (RIPA). A total of 30 g of 
total proteins were separated in a 4%-20% gradient gel 
(Bio-Rad Laboratories, Hercules, CA, USA). Proteins 
were then transferred to a polyvinylidene fluoride 
(PVDF) membrane. The membranes were blocked and 
incubated overnight at 4 °C with the primary anti-PBR 
antibody (anti-PBR, TSPO) (1:500, ab109497, Abcam, 
Cambridge, UK). Besides, GAPDH was used to 
normalize protein loading and transfer (ab37168, 
Abcam, Cambridge, UK). The membranes were then 
incubated with the corresponding secondary antibody 
and blots were developed by chemiluminescence. The 
intensity of bands was quantified using ImageJ 1.51j 
software (National Institutes of Health, Bethesda, MD, 
USA). Normalized band intensities were reported as 
relative protein expression. 
Real time qPCR 
Total RNA isolated from control and HT-fed 
mice half-brain were kindly provided by A. J. 
Kiliaan’s working group. We processed the samples 
with DNAse I treatment (Roche, Mannheim, 
Germany) to avoid contaminations from genomic 
DNA. The isolated RNA was quantified (Nanodrop, 
Thermo Scientific). One µg of total RNA was reverse 





transcribed into first-strand cDNA using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Indianapolis, IN). 
The forward (FW) and reverse (RV) primer 
sequences (Sigma-Aldrich) used were: tspo (FW, 
ggatctttccagaacatcag; RV, acgtacaaagtaggctcc), Il1b 
(FW, ggatgatgatgataacctgc; RV, catggagaatatcacttg 
ttgg Arg1 (FW, ctgacctatgtgtcatttgg; RV, 
catctgggaactttcctttc), Gapdh (FW, ctggagaaacct 
gccaagta; RV, tgttgctgtagccgtattca), Tnf (FW, 
tgagactgagatcta, RV, ctagggtacgatcgatagc) and Cd163 
(FW, agtctgctcacgatacatag, RV, tccttctggaatagattggg). 
Rt-qPCR was performed using the Rotor-Gene 
SYBR Green master mix with the Rotor-Gene Q device 
(Qiagen). Relative gene expression changes were 
assessed using the ∆∆Ct method, with Gapdh as a 
housekeeping gene. 
Statistical analysis 
All statistical analyses were performed using 
SigmaPlot (Systat Software GmbH, Erkrath, 
Germany). All data were tested for normality and 
equal variance using the Shapiro-Wilk and 
Brown-Forsythe tests, respectively. 
The sample sizes were calculated a priori during 
the animal ethics dossier application. They were 
determined based on effect size (p = 0.05, statistical 
power: 0.80), mortality rates, and a previous stroke 
study [46], where we investigated the therapeutic 
effect of a dietary approach on brain inflammation 
assessed by [18F]DPA-714 PET imaging study in 
ischemic mice. We set the minimal detectable 
difference in means to 0.2 and the expected standard 
deviation of residuals to 0.1. 
Peripheral markers data were analysed using 
unpaired t-tests for two-group comparisons. 
Longitudinal tracking of stroke-associated parameters 
([18F]DPA-714 uptake, CBF, ADC, behaviour, etc.) 
were analysed using two-way ANOVA followed by 
Holm Sidak’s post hoc test for multiple comparisons. 
In all statistical tests, differences were considered 
when p < 0.05. Data are expressed and depicted as 
means ± sd if not specified. 
Results 
T2-weighted MRI-defined edema is not affected 
by HT 
First, we aimed at evaluating the impact of a HT 
diet on the T2w-MRI-defined edema volume 
delineated using a semi-automated atlas-based 
thresholding method as described by Mulder et al. 
(2017) [43]. This analysis method was established 
within the first week post ischemia and thus, we only 
reported quantification of T2w-MRI lesion size within 
the first week. The dataset passed the Shapiro-Wilk (p 
= 0.44) and Brown-Forsythe (p = 0.25) tests. Two-way 
RM ANOVA indicated main effect of time (p < 0.001) 
but not of treatment (p = 0.82) or interaction (p = 0.95). 
For all stroke mice, edema decreased over time. 
Edema volumes on day 3 (control: p = 0.01, HT: p = 
0.005) and 7 (p < 0.001 for both groups) were 
significantly reduced compared to day 1 post 
ischemia for both control and HT-fed mice. Similarly, 
T2w-MRI-defined edema volumes on day 7 (p < 0.001 
for both groups) were significantly smaller compared 
to day 3 post ischemia (Sidak’s post hoc test). 
No treatment effect was observed on the mean 
T2w-MR edema volume for each time point (Figure 2). 
Importantly, edema volumes on day 1 were 
comparable between the two groups (Sidak’s post hoc 
test, p = 0.80). 
Individual follow-ups of the T2w-MRI edema are 
shown in Supplementary Figure S2. 
Hydroxytyrosol does not improve reperfusion 
of the infarct 
We tracked CBF changes associated to an 
ischemic injury and assessed the effect of a HT diet at 
days 1, 3, 7, 14, 21 and 30 post ischemia using 
FAIR-RARE MRI (Figure 3A). Mean CBF and ratios 
dataset passed the Shapiro-Wilk and Brown-Forsythe 
tests. 
Repeated measures ANOVA did not indicate 
any main effect of time (p = 0.21) or treatment (p = 
0.88) or interaction (p = 0.61) on mean CBF values. 
Post hoc test was not performed for this dataset. In 
overall, the mean CBF values of both control and HT 
mice did not significantly change over time, in both 
infarct and contralateral side. 
Longitudinal intra-group comparison indicated 
that CBF values within the infarct at days 1, 3 and 7 
were decreased compared to the corresponding area 
in the unaffected hemisphere in all stroke mice (RM 
ANOVA, time, p = 0.001). Lower CBF values within 
the infarct of control mice were observed at days 1 
(infarct: 49.7 ± 30.7 mL/100 g/min, contralateral: 
103.4 ± 14.8 mL/100 g/min, Sidak’s post hoc test, p = 
0.003) until day 7 (infarct: 71.4 ± 15.2 mL/100 g/min, 
contralateral: 96.3 ± 28.6 mL/100 g/min, Sidak’s post 
hoc test, p = 0.033) compared to the contralateral 
region. Similarly, mean CBF values within the infarct 
of HT-fed mice at day 1 (infarct 47.8 ± 41.8 mL/100 
g/min; contralateral: 63.5 ± 32.5 mL/100 g/min) until 
day 7 post ischemia (infarct: 80.8 ± 35.3 mL/100 
g/min, contralateral: 119.2 ± 30.5 mL/100 g/min, 
Sidak’s post hoc test, p = 0.049) were significantly 
lower than in the contralateral hemisphere (Figure 
3B). 






Figure 2. Longitudinal monitoring of the edema volume using T2w-MR imaging after ischemic stroke. (A) Representative T2w-MR images from control and HT-fed mice 
acquired at days 1, 3 and 7 post ischemia. The edema volume (white) was delineated by an atlas-based thresholding approach. (B) Edema volume decreased from day 3 post ischemia for either 
control (green, n = 8) and HT (red, n = 8) fed mice. No treatment effect was observed on edema volume. Individual data are plotted in mm3. Statistical analysis was carried out with two-way 
RM ANOVA followed by Holm Sidak’s post hoc test for multiple comparisons (* p < 0.05, ** p < 0.01, *** p < 0.005; * vs. day 3, # vs. day 7). 
 
To reduce intra-individual variability, we also 
assessed the infarct-to-contralateral ratio at each time 
point. Infarct-to-contralateral CBF ratios dataset 
passed the Shapiro-Wilk (p = 0.35) and 
Brown-Forsythe (p = 0.93) tests. Two-way RM 
ANOVA indicated main effect of time (p < 0.001) but 
not of the treatment (p = 0.43) or interaction (p = 0.69). 
Data are shown in Figure S3. 
Hydroxytyrosol does not affect the water 
diffusion coefficient 
Apparent diffusion coefficients (ADCs) were 
assessed by DTI EPI MRI from a series of echo planar 
imaging (EPI)-images for each dietary group at days 
1, 3, 7, 14, 21 and 30 post ischemia (Figure 4A). The 
ADC dataset passed the Shapiro-Wilk (p = 0.11) and 
Brown-Forsythe (p = 0.24) tests. Repeated measures 
ANOVA indicated main effect of time (p < 0.001) and 
time * region (p < 0.001) but not of treatment (p = 0.34). 
In both experimental groups, the mean ADC 
value in the contralateral hemisphere did not change 
over time (p = 0.062, Sidak’s post hoc test) (Figure 4B). 
In the infarct hemisphere, time effect was observed in 
both groups (p < 0.001, Sidak’s post hoc): ADC value 
was significantly increased at days 14 (p = 0.009), 21 (p 
< 0.001) and 30 (p < 0.001) post ischemia compared to 
day 1 post ischemia. Moreover, ADC values 
significantly increased from day 3 to day 21 (p = 0.001) 
and 30 (p < 0.001) post ischemia. 






Figure 3. Longitudinal monitoring of the mean cerebral blood flow by FAIR-MRI 1, 3, 7, 14, 21 and 30 days after stroke. CBF was assessed within the infarct defined on the 
T2w-MR images from day 1 post ischemia and this mirrored ROI in the contralateral side in control (green) and HT-fed (red) mice. (A) Representative CBF images at days 1, 3, 7, 14, 21 and 
30 post ischemia for both control (upper row) and HT-fed mice (lower row) and the corresponding T2w-MR image at day 1 post ischemia. CBF maps showed hypoperfused infarct regions 
within the first week for both groups. At later time points, CBF was partially recovered in both groups. (B) Quantification of the mean CBF within the infarct and contralateral striatum showed 
no treatment effect on tissue reperfusion. Values represent mean ± sd (n = 8 per group). Statistical analysis was carried out with RM ANOVA followed by Holm Sidak’s post hoc test for 
multiple comparisons (# p < 0.05, ## p < 0.01, ### p < 0.005, # vs. contralateral). 
 
Similarly, temporal dynamic of the 
infarct-to-contralateral ADC ratio indicated main 
effect of time (p < 0.001) but not of the treatment (p = 
0.81) or interaction (p = 0.82) (Figure S4). 
Infarct-to-contralateral ratio on day 1 post ischemia 
was significantly increased compared to days 14 (p < 
0.001), 21 (p < 0.001) and 30 (p < 0.001) (Sidak’s post 
hoc test). Besides, ADC ratios at days 3 and 7 were 
significantly decreased compared to day 30 and/or 
day 14 post ischemia, indicating that the ADC ratio 
recovered within days 7 and 14 post ischemia. 
Hydroxytyrosol does not affect TSPO 
expression as assessed by [18F]DPA-714 PET 
imaging 
[18F]DPA-714 uptake dataset passed the 
Shapiro-Wilk (p = 0.70) and Brown-Forsythe (p = 0.51) 
tests. Two-way RM ANOVA indicated no main effect 
of treatment, time and interaction on tracer uptake 
within the infarct (Figure 5A-B), and in the 
contralateral striatum (Figure 5A-B), suggesting that 
both control and HT-fed mice showed same tracer 
uptake dynamic over time. Similarly, relative changes 
in [18F]DPA-714 uptake did not indicate any 
significant difference between treatment groups. 
Elevated [18F]DPA-714 uptake was observed 
within and beyond the ischemic lesion defined by 
T2w-MR image on day 1 post ischemia (Figure 5A). 
Significant difference in tracer uptake was observed 
between the infarct and contralateral striatum over 
time, for both treatment groups (Figure 5B). Two-way 
RM ANOVA revealed a significant effect of the brain 
region (p < 0.001) but not of time (control: p = 0.36; HT: 
p = 0.15) or interaction region * time (control: p = 0.59; 
HT: p = 0.71). Details are given in the Figure S5. 
Infarct-to-contralateral striatum uptake ratios 
did not differ between control and HT-fed mice over 
time (two-way RM ANOVA followed by Sidak’s post 
hoc test, treatment: p = 0.13, time: p = 0.11, treatment * 
time: p = 0.75) (Figure 5C). 






Figure 4. Hydroxytyrosol does not affect the microstructure after stroke. Apparent diffusion coefficient was assessed within the infarct defined on the T2w-MR images from day 1 
post ischemia and a mirrored reference ROI (contralateral) in control (green) and HT-fed (red) mice. (A) Representative diffusion-weighted images (with the highest b value of 2400 s/mm2) 
and the respective ADC map at days 1, 3, 7, 14, 21 and 30 days post ischemia for each experimental group. (B) Time course of the ADC values determined in the infarct and the contralateral 
area in control (green) and HT-fed (red) mice. RM ANOVA indicated main effect of time (p < 0.001) and time * region (p < 0.001) but not of treatment (p = 0.34). For both groups, the mean 
ADC value within the infarct hemisphere significantly recovered from day 14 post ischemia. Values represent mean ± sd. Control: n = 8, HT: n = 8. Statistical analysis was carried out with RM 









Figure 5. A HT diet does not affect TSPO expression as detected by [18F]DPA-714 PET imaging after ischemic injury. The mice were scanned for [18F]DPA-714 PET at days 
7, 14, 21 and 30 post ischemia to assess TSPO expression within the infarct (white circle) and the contralateral striatum. The percentage of injected dose per millimetre (%ID/mL) was 
quantified within both regions. (A) Representative axial co-registered [18F]DPA-714-PET-CT images of a mouse fed with either control (upper row) or HT (lower row) diet after a 30 min 
tMCAo with comparable T2w-infarct on day 1 post ischemia (white delineation). (B) Similar uptake was measured between both groups either within the infarct or contralateral striatum over 
time. (C) Infarct-to-contralateral ratios did not differ over time, indicative of constant chronic neuroinflammatory reaction in the infarcted hemisphere compared to the contralateral side (p 
> 0.05). Values represent mean ± sd. Control: n = 8, HT: n = 8. Statistical analysis was carried out with two-way RM ANOVA. 
 
 
Figure 6. A HT diet induces a slight increase in TSPO expression at day 35 post ischemia. (A) Representative TSPO staining within the infarct and contralateral side obtained by 
immunohistochemistry at day 35 post ischemia from both control and HT-fed mice (white scale bar: 30 µm, black scale bar: 8 µm). For both experimental groups, immune cells and endothelial 
cells showed TSPO immunoreactivity. A HT diet slightly increased TSPO-related inflammatory level (n = 3/group, with 3 fields of view per animal). (B) Representative western blot for TSPO 
from brain protein extracts obtained at day 35 post ischemia (n = 6/group). A HT diet did not change TSPO protein levels in both the infarct (I) and contralateral (C) hemispheres at day 35 
post ischemia. Values are normalized relative to GAPDH band. Statistical analysis was carried out with two-way ANOVA for multiple comparisons followed by Holm Sidak’s post hoc test for 
multiple comparisons. Values represent mean ± sd. (*p < 0.05, ** p < 0.01, ***p < 0.005; * vs. contralateral, # vs. diet). 
 
Cross-validation of [18F]DPA-714 PET with 
TSPO expression at day 35 post ischemia 
We cross-validated [18F]DPA-714 PET images 
with TSPO by immunohistochemistry (IHC) and 
western blot (Figure 6, Figure S6). 
The stroke effect on TSPO expression levels was 
observed by IHC, indicated by significant higher 
percentage of stained area within the infarct 
compared to the contralateral side for both dietary 
groups (Figure 6A). Dietary effect was observed 
within the infarct, indicated by a slight increase in 
TSPO expression in HT-fed mice (2.11 ± 0.8%) 
compared to control mice (0.91 ± 0.42%, p = 0.011) 
(Sidak’s post hoc test, p < 0.001) (Figure 6A) while no 
dietary effect was observed in the contralateral side 
(control: 0.40 ± 0.09%, HT: 0.44 ± 0.13%, p = 0.83). 
On the other hand, no significant difference in 
TSPO expression at the protein level (western blot) 
was observed between the treatment groups, in both 
infarct (control: 0.74 ± 0.36, HT: 0.65 ± 0.15, Sidak’s 
post hoc test, p = 0.89) and contralateral (control: 0.28 
± 0.13, HT: 0.32 ± 0.09, Sidak’s post hoc test, p = 0.97) 
hemispheres (Figure 6B). 
Cellular localization of TSPO expression 
within the ischemic lesion at day 35 post 
ischemia 
The brains were double stained for TSPO and 
Iba-1 or GFAP or F4/80 at day 35 post ischemia to 
identify the cellular sources of TSPO. Co-localization 
of different cell markers indicated TSPO to be partly 
expressed by Iba-1+ and F4/80+ (microglia/ 
macrophages) cells for both experimental groups. 
TSPO expression was not found in GFAP+ (astrocytes) 
cells in both dietary groups (Figure 7). 
Quantification of the images is reported in 
Figure S7. For both Iba-1+ and F4/80+, treatment effect 
was observed on TSPO- cells, indicated by the 
significant increase of Iba-1+TSPO- and F4/80+TSPO- 
(p < 0.005) with HT. Besides, HT significantly 
increased the number of Iba-1+CD163+ cells (p = 0.01). 






Figure 7. TSPO is mainly expressed in microglia/macrophages within the infarct at day 35 post ischemia. Co-localization of TSPO with immune cells markers such as Iba-1, 
GFAP and F4/80 at day 35 post ischemia highlighted strong microgliosis independent of TSPO expression. No or minor colocalization of GFAP or F4/80 positive cells with TSPO was found. 
Nuclei are counterstained with DAPI (blue). White scale bar: 40 µm. 






Figure 8. HT increases Iba-1 positive cells number within the infarct at day 35 post ischemia. (A) Representative immunohistochemistry for Iba-1 in brain of control (upper row) 
and HT-fed (lower row) mice within the infarct and at the contralateral side 35 days after tMCAo. Iba-1 positive cells within the ischemic lesion exhibited an amoeboid morphology in brain 
of HT-fed mice compared to control mice brain (ramified shape) (black scale bar: 50 µm, white bar: 9 µm). (B) Quantification of the percentage of Iba-1 stained area showed increased Iba-1 
positive area within the infarct in HT-fed mice (red) compared to controls (control), indicative of HT’s immunomodulatory effect on Iba-1 positive cells (n = 4/group, with 3 fields of view per 
region). (C) Most of the Iba-1 positive cells co-expressed CD163, an anti-inflammatory marker (red scale bar: 10 µm). (D) Gene expression confirmed immunofluorescence data and indicated 
a trend toward an increased expression of anti-inflammatory markers after HT treatment at day 35 post ischemia. Statistical analysis was carried out with two-way RM ANOVA followed by 
Holm Sidak’s post hoc test for multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.005, * vs. contralateral, # vs. diet). 
 
Hydroxytyrosol extensively increases the 
number of Iba-1 positive cells within the infarct 
at day 35 post ischemia 
We found very prominent microglial activation 
within the infarct in HT-fed mice compared to control 
mice, as evidenced by histology (Figures 8A-B). 
Stroke effect was observed in both groups 
(two-way RM ANOVA, p < 0.001): the percentage of 
Iba-1 positive area within the infarct was significantly 
increased compared to the contralateral striatum, for 
both control (p = 0.008) and HT-fed mice (p < 0.001) 
(Sidak’s post hoc test) (Figure 8A). 
A dietary effect was observed within the infarct 
(two-way RM ANOVA, p = 0.001): the percentage of 
Iba-1 positive area in HT-fed mice was higher 
compared to control mice (p < 0.001, Sidak’s post hoc 
test). The same tendency was observed in brain tissue 
collected at day 7 post ischemia, where an increased 
percentage of Iba-1+ cells was found within the 
ischemia in HT-fed mice compared to control mice 
(Figure S8). Iba-1 positive cells within the ischemic 
lesion exhibited activated/reactive morphology with 
hypertrophic cell bodies and very short processes in 
brain of HT-fed mice in comparison to the more 
ramified morphology of Iba-1 positive cells in control 
mice brain (Figure 8A). No diet effect was observed in 
the contralateral side (p = 0.98, Sidak’s post hoc test). 
The correlation between TSPO and Iba-1 
expression indicated a linear relationship between 
both markers (R2 = 0.80, Figure S9). 
To investigate the anti-inflammatory potential of 
HT, we characterized the Iba-1+ cells population 
co-expressing CD163, a general anti-inflammatory 
marker (Figure 8C). We observed a significant 
treatment effect on the number of Iba-1+CD163+ cells 
(Figure S7B), indicating that HT may increase the 
number of anti-inflammatory microglia/macrophages 
at late time points. 
Besides, we investigated gene expression of pro- 
and anti-inflammatory markers at day 35 post 
ischemia (Figure 8D). No significant treatment effect 
was observed on tspo, cd163, tnf and Il-1β gene 
expression in both infarct and contralateral 





hemisphere (p > 0.05). Significant increase of the 
anti-inflammatory marker arginase 1 (arg1) was 
observed in the contralateral hemisphere (Sidak’s post 
hoc test, p = 0.043). 
Hydroxytyrosol improves strength recovery 
within first two weeks after stroke 
Functional deficits were assessed with a set of 
behavioural and motor tests in all mice before and 
after ischemia following the timeline shown in Figure 
1. 
Open field (Figure 9) 
Exploratory behaviour, activity, and anxiety 
were assessed using the open field test (Figure 9). At 
days 7 and 30 post ischemia, all mice travelled a 
shorter distance (Figure 9.A) at a lower velocity 
(Figure 9B) compared to baseline. No difference was 
observed between days 7 and 30 in both groups. No 
dietary effects were observed on distance moved and 
velocity (two-way RM ANOVA, p > 0.05). 
All mice visited less frequently the centre and 
the periphery of the arena at days 7 and 30 compared 
to baseline while no change was observed in the 
corners over time. No dietary effects were observed 
on the frequency of entrance in each zone (Figure 9C). 
The time spent in the central zone significantly 
decreased at day 30 post ischemia in control mice 
compared to baseline (p = 0.048) while no difference 
was observed in HT-fed mice. No difference in time 
spent along the peripheral zones and the corners was 
observed over time for both dietary groups. No diet 
effect was observed in time spent in the different 
corners of the open field (Figure 9D). 
Grip strength test (Figure 10) 
Forelimb (trapeze) and total-limb (grid) grip 
strength test revealed no significant difference in 
baseline level (day 0, D0) between groups, for both 
fore- and total limbs (p > 0.05). 
 
 
Figure 9. Hydroxytyrosol does not improve locomotion. Distance moved [cm], velocity [cm/s], frequency and duration [s] were assessed like index of locomotion and anxiety. Overall, 
there was no dietary effect observed on locomotor activity and anxiety level assessed by open field. The time spent in the central zone significantly decreased at day 30 post ischemia in control 
mice compared to baseline while no difference was observed in HT-fed mice. Values represent mean ± sd. Control: n = 8, HT: n = 8. Statistical analysis was carried out with two-way RM 
ANOVA followed by Holm Sidak’s post hoc test for multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.005). 






Figure 10. Hydroxytyrosol improves strength recovery of the forelimbs after ischemia. (A) Grip test revealed a HT diet improved forelimbs strength and thus recovery at day 14 
post ischemia (p = 0.031). In control mice, the grip strength was decreased 14 days after stroke while no difference was observed in HT-fed mice (p = 0.031). (B) However, no difference was 
observed in total limbs strength over time. Values represent mean ± sd. Control: n = 8, HT: n = 8. Statistical analysis was carried out with two-way RM ANOVA followed by Holm Sidak’s post 
hoc test for multiple comparisons (*p < 0.05). 
 
Within group comparisons a significant 
reduction was observed in forepaws strength of 
control mice between baseline (D0: 115.0 ± 32.7 gf) and 
day 14 (D14: 80.5 ± 17.0 gf) post ischemia (two-way 
RM ANOVA, p = 0.031). Within the HT-fed mice 
group, no significant decrease in strength was 
observed between pre- and post-ischemia assessment 
(two-way RM ANOVA, p > 0.05). However, diet 
group comparisons indicated a significant 
improvement in grip strength in HT-fed mice when 
compared to control at day 14 post ischemia (two-way 
RM ANOVA, p = 0.031) (Figure 10A). 
Within group comparisons total limbs strength 
baselines did not differ from the post-stroke follow up 
at both day 14 and 30 post ischemia (p > 0.05), for both 
control and HT-fed mice (Figure 10B). 
Discussion 
The Mediterranean diet is recommended as a 
healthy dietary pattern to prevent cardiovascular 
diseases and neurodegenerative processes [22]. 
Hydroxytyrosol, the main phenolic compound of the 
EVOOO, is well-known for its antioxidant and 
anti-inflammatory properties, protecting vascular 
health [47]. In this context, HT dietary intervention 
seems a promising multifaceted approach to prevent 
but also to slow down the progression of cardio- and 
cerebrovascular diseases. In this study, we 
investigated the anti-inflammatory, cerebrovascular 
and functional outcomes after dietary treatment with 
HT in the post ischemic phase. HT strongly increased 
numbers of Iba-1+ microglia/macrophages 
population also expressing CD163 (anti-inflammatory 
marker) within the infarct region, inducing a slight 
increase in TSPO expression not detected by 
[18F]DPA-714 PET. 
Interestingly, HT improved strength recovery 
within the first two weeks while no treatment effect 
was observed on the selected in vivo imaging 
parameters. Overall, we showed that a prolonged 
dietary intervention with HT modulated the glial 
response and enhanced muscle recovery during the 
post ischemic phase. 
Edema 
Anti-inflammatory olive oil phenols have been 
considered as neuroprotective nutraceuticals usable 
in ischemic brain injury prevention. Mohagheghi et al. 
(2010) investigated the impact of dietary VOO on 
brain infarct and showed that 1-month pretreatment 
reduced infarct volume in rats [48]. The same 
protective effect was observed with olive leaf extract 
[49] containing HT. 
Here, T2w-MR imaging was used to delineate the 
infarct area following the method previously reported 
[43,50]. No treatment effect was observed on the 
T2w-MR edema volume. While VOO and 
hydroxytyrosol administrations prior ischemia are 
able to decrease infarct volume, our data suggested no 
therapeutic effect of HT within the first week on 
infarct size. 
Similarly, cytotoxic edema was identified by 
enhanced hyperintense signals on DW images. Our 
results also indicated no treatment effect on the mean 
ADC value over time. While pretreatment with 
HT-containing virgin olive oil strongly reduced brain 
free water content after MCAo in rats [51], HT as a 
therapy does not show any protective effect on edema 
and/or water compartmentalization after stroke. 
Vascular parameters 
Vascular endothelial cells are central players in 
the inflammatory cascade. Under physiological 
conditions, they regulate blood flow and control 
vessel permeability. Following stroke, endothelial 
cells are activated by a plethora of signalling 





molecules, leading to a decreased CBF, increased 
vessel-wall leakage and subsequent infiltration of 
PNS immune cells at the site of inflammation. HT, as 
an antioxidant, has been reported beneficial against 
vascular diseases by improving endothelial functions 
[52]. In in vitro models, HT suppressed inflammatory 
angiogenesis by inhibiting endothelial cell 
proliferation [27] and promoting apoptosis [53,54]. 
In our study, we did not detect any treatment 
effect on CBF. In a recent paper, Calahorra et al (2019) 
indicated that HT-fed mice had increased CBF in the 
right hippocampus and left cortex at days 7 and 35 
post ischemia compared to control mice. However, 
the authors did not measure CBF within the infarct 
region. 
Additionally, we used nitric oxide (NO) as a 
peripheral marker to assess vascular tissue at day 35 
post ischemia. Lausada et al. (2015) showed that 
EVOO consumption prior and after experimental 
stroke was protective against iNOS activation in the 
penumbral region within the first days post ischemia 
(73). In our study, we did not observe any treatment 
effect on NO levels, as previously reported by 
Calahorra et al. (2019) [34]. The peak of iNOS 
expression was observed within two weeks post 
ischemia but resolved after one month post ischemia 
(71,72), which may explain why we did not observe 
any effect at day 35 post ischemia. 
Anti-inflammatory properties 
Stroke causes a strong inflammatory reaction 
within infarct and peri-infarct areas involving 
heterogeneous immune cell populations [55,56]. 
Observations indicated that microglia/macrophages 
and astrocytes actively modulate the inflammatory 
cascade at different stages of the disease [56,57]. They 
are initial responders to injury and contribute to 
cognitive deficit/recovery at later stages, depending 
on their activation state, ranging from a more 
pro-inflammatory to an anti-inflammatory state, 
modulating both neuronal cell death and tissue 
restoration, respectively [58,59]. 
Translocator protein (TSPO) PET imaging 
provides a non-invasive method to repeatedly access 
neuroinflammation/glial activity through the disease 
time course [55,60-62]. TSPO is expressed at low level 
under normal physiological conditions while its 
expression increases in activated glial cells in 
response to brain injury [63]. In a rat stroke model, 
[18F]DPA-714 (TSPO) signal within the infarcted area 
peaked around day 10-14 post ischemia, a signal 
mostly induced by microglia/macrophages [64] while 
a greater astrocytic contribution to the signal was 
observed at latter time points. Therefore, TSPO 
expression by microglia/infiltrating macrophages 
and astrocytes seems to be spatiotemporally 
dependent [62,64-66]. However, its differential 
expression pattern and precise function in 
inflammatory conditions remain unclear. 
The impact of HT on immune cells is still 
sparsely explored [34]. Here, we showed that HT 
drastically increased the number of Iba-1+ cells 
(microglia/macrophages) within the infarcted brain 
area at day 35 post ischemia without any effect on the 
contralateral hemisphere. No significant difference 
was observed in F4/80 expression, a marker mostly 
upregulated in macrophages and at a low level in 
resting microglia, indicating that HT might 
preferentially stimulate the proliferation of microglial 
cells. However, further studies are needed to further 
characterize HT induced changes in the glial 
compartment at earlier time points. As a first 
indication, increased Iba-1 and CD68 immuno-
reactivity was also observed at day 7 post ischemia. 
The accumulation of those numerous cells could 
not be detected by using [18F]DPA-714 (TSPO) PET 
imaging while a positive correlation was observed 
between the amount of Iba-1+ area and radiotracer 
uptake. Immunoreactivity is the gold standard to 
validate in vivo PET imaging due to its higher 
sensitivity. Our TSPO IHC data indicated a two-fold 
increase in TSPO expression (going from 1% to 2% 
TSPO+ area) in HT-fed mice while no significant 
changes were observed in TSPO-PET and WB. The 
detection of these changes presumably lies beyond the 
sensitivity of the PET technique. Additionally, small 
changes could also be hidden by partial volume 
effects (due to high uptake observed in surrounding 
glands and fatty tissues), the low number of animals 
and/or the inherent differences in quantification 
methods (2D vs. 3D). Further studies are needed to 
characterize HT induced changes in the glial 
compartment on a tissue level at earlier time points 
after stroke. 
In a previous study, we investigated the 
neurorestorative efficacy of a dietary approach on 
TSPO expression as well [46]. Results indicated that in 
vivo DPA-714 PET was able to detect therapy effect on 
TSPO expression at late time points. However, the 
diet used in the latter study was a multicomponent 
diet that might induce a stronger therapeutic effect 
compared to our single component diet. Thus, we 
hypothesise that the dynamic range of changes on 
TSPO expression induced by a HT diet might be 
hidden by the stroke effect and PET sensitivity. HT 
slightly stimulates TSPO overexpression on a tissue 
level. 
To our knowledge, it remains unclear if a larger 
Iba-1+ cell population is more beneficial than resting 
microglial cells at late stages, while “active-shaped” 





microglia indicated homeostatic imbalance. Here, our 
results indicated that there was no benefit from late 
“activated” microglial on stroke outcomes. However, 
Lartey et al. (2014) demonstrated a positive 
correlation between three microglial related proteins 
(TSPO, CD11b and CD68) and motor function 
(rotarod) over the first 22 days following stroke in 
mice [67], indicating that better motor outcome is 
associated to increased microglial activity and/or 
number. 
We further characterized the Iba-1+ cell 
populations and the inflammatory environment by 
assessing the expression level of common markers. 
CD163 gene expression was similar in both groups as 
its fluorescence intensity, suggesting that the 
apparent increase in CD163 in the HT group was 
related to the overall increase in Iba-1+ cells. 
Moreover, the increased number of Iba-1+(CD163+) 
cells in the HT-fed group may partly explain the 
increase in Arg1 and Il-1β gene expression. Overall, 
our results supported the potential anti-inflammatory 
effect of HT during the post ischemic phase, indicated 
by higher expression of anti-inflammatory markers, 
while no clear-cut effect was observed. Future 
investigations should focus on a more extensive 
evaluation of the anti- and pro-inflammatory 
microglial polarization markers using a dedicated 
study design and appropriate techniques (scRNA and 
spatial transcriptomics) to conclude on the potential 
immunomodulatory effect of HT. 
Cellular and scarce preclinical studies further 
support the anti-inflammatory properties of HT 
[22,30,68]. Among others, the mechanisms by which 
HT is able to prevent and counteract inflammation 
include reducing oxidative stress and free radical 
production [30]. Pretreatment with HT was shown to 
inhibit cyclooxygenase-2 (COX-2) and iNOS genes 
expression in LPS challenged J774 murine 
macrophages [30] while no effect was observed when 
HT was added 12 hours after LPS. Besides, HT 
pre-cultured RAW264.7 murine macrophages cells 
also showed that HT decreased NO, prostaglandin E2 
(PGE2) production and secretion of pro-inflammatory 
cytokines such as IL-1β, IL-6 and TNF-α [23] in a 
concentration-dependent manner. In a mouse model 
of systemic inflammation, pretreatment with HT also 
reduced COX-2 and TNF-α [29]. 
Altogether, these studies support the preventive 
rather than the curative effects of HT on the 
inflammatory cascade. Accordingly, the famous 
PREDIMED clinical study reported the preventive 
effect of the Mediterranean diet against stroke and 
cardiovascular events [26] while its therapeutic effect 
has been scarcely investigated. We do believe that HT, 
as a single component diet, has a weaker effect than a 
multicomponent diet containing other Mediterranean 
components. As stated before, in our previous work, 
we investigated the therapy effect of a 
multicomponent diet on stroke outcomes and 
reported significant effects on brain inflammation 
[46]. Therefore, we do support the use of the 
Mediterranean diet as a therapeutic approach since 
HT, as a single component, already showed 
interesting modulatory effects on stroke outcomes. 
Antioxidant properties 
The generation and release of oxygen free 
radicals (ROS) increase in acute disease is leading to 
high oxidative stress, associated with increased 
cellular death, blood-brain barrier disruption and 
inflammation [69]. 
One of the main beneficial health effects of HT 
was so far related to its ROS-scavenging properties 
and its ability to activate endogenous antioxidant 
systems. The potential antioxidant effect assessed by 
the level of the lipid peroxidation biomarker 
thiobarbituric acid reactive substances (TBARS) in 
serum did not indicate a significant difference 
between treatment groups at day 35 post ischemia. 
We suppose that release of ROS/RNS is an early 
process that is already resolved at the late stages of 
the disease [34,70]. 
Limitations of the study 
First, the therapeutic efficiency is dependent on 
the dietary intake. Within the first week, the animals 
reduced their food intake and lost weight. Therefore, 
the potential acute therapeutic effect of HT on 
oxidative stress and inflammation could be 
underestimated within the first week. 
The sample size was calculated based on a 
previous study where we investigated the therapeutic 
effect of a dietary approach on [18F]DPA-714 tracer 
uptake in ischemic mice. Moreover, the same groups 
were used to perform MR imaging and behavioural 
tests. Due to the large variability between animals in 
behaviour, the statistical power of the different tested 
parameters is below 0.80. Post-analysis of the data 
indicated that statistical power for the velocity 
assessed by the pole test and strength were of 0.84 and 
0.71, respectively. However, the statistical power was 
on the low side for rotarod and open field, with 0.36 
and 0.63 respectively. Therefore, the protective 
potential of HT on cognition and motor functions 
might be under- and/or overestimated. In our study, 
we showed that a prolonged HT treatment in the post 
ischemic phase improved forepaw strength recovery 
(power: 0.71). This finding was supported by previous 
stroke studies [55, 72], that observed improved motor 
functions after a single injection of HT in a 120 min 





tMCAo rodent model [55] and improved forelimbs 
strength in the acute phase of the disease [55]. Overall, 
we concluded that HT could improve motor 
functions. 
Conclusion 
The understanding of how nutrition and in 
particular components of the Mediterranean diet may 
help treatment after brain injury has grown in recent 
years. In this context, we performed a longitudinal in 
vivo imaging study of the neuroinflammation, 
cerebrovascular and functional outcomes after a 
prolonged HT-enriched diet in an experimental stroke 
model. Data presented in this work indicated that HT 
has immunomodulatory effects by increasing the 
number of Iba-1+ microglia/macrophages in the post 
ischemic tissue. Analysis of inflammation-related 
markers expression supported that HT may favour an 
anti-inflammatory state. Further studies should focus 
on in-depth characterization of the pro- and anti- 
inflammatory markers expression using dedicated 
techniques (scRNA and spatial transcriptomics). 
Overall, molecular changes induced by HT, as a 
single component of the Mediterranean diet, were not 
detected by in vivo imaging while we did observe a 
significant positive effect on muscle strength 
recovery. Therefore, we do support the use of the 
Mediterranean diet as a therapeutic approach since 
HT, as a single component, already showed 
interesting molecular modulatory effects on stroke 
outcomes. 
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